Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Filtros adicionais











Tipo de estudo
Intervalo de ano
2.
Eur J Intern Med ; 64: 63-71, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30904433

RESUMO

PURPOSE: The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality. METHODS: Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015.Patients were stratified into three age groups:<65 years,65 to 80 years,and ≥ 80 years.The area under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of the CCI to predict mortality risk. RESULTS: A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502 ≥ 80 years) were enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age groups.Patients ≥80 years who underwent surgery were significantly lower compared with other age groups (14.3%,65 years; 20.5%,65-79 years; 31.3%,≥80 years). In-hospital mortality was lower in the <65-year group (20.3%,<65 years;30.1%,65-79 years;34.7%,≥80 years;p < 0.001) as well as 1-year mortality (3.2%, <65 years; 5.5%, 65-80 years;7.6%,≥80 years; p = 0.003).Independent predictors of mortality were age ≥ 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32-3.34), CCI ≥ 3 (HR:1.62; 95% CI:1.39-1.88),and non-performed surgery (HR:1.64;95% CI:11.16-1.58).When the three age groups were compared,the AUROC curve for CCI was significantly larger for patients aged <65 years(p < 0.001) for both in-hospital and 1-year mortality. CONCLUSION: There were no differences in the clinical presentation of IE between the groups. Age ≥ 80 years, high comorbidity (measured by CCI),and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in the <65-year group.

5.
J Antimicrob Chemother ; 68(8): 1917-25, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23557925

RESUMO

BACKGROUND: Conflicting evidence has been reported on the impact of ertapenem use on the susceptibility of Pseudomonas spp. to group 2 carbapenems. No extensive data for Acinetobacter baumannii are currently available. METHODS: A retrospective time-series segmented regression analysis was conducted in a tertiary centre from January 2001 to December 2011. Ertapenem was introduced in January 2005. Antimicrobial drug use was defined as the number of defined daily doses/100 patient-days (DDDs/100 PDs). Susceptibility (CLSI) was measured in terms of proportion and incidence density. RESULTS: Mean monthly use of imipenem was 2.9 ±â€Š0.9 DDDs/100 PDs, as compared with 1.2 ±â€Š0.7 DDDs/100 PDs for meropenem and 1.0 ±â€Š0.7 DDDs/100 PDs for ertapenem (after its introduction). After ertapenem adoption, a downward trend was seen in the use of imipenem (P = 0.016) and ciprofloxacin (P = 0.004). A total of 6272 Pseudomonas aeruginosa and 1093 A. baumannii isolates were evaluated. Susceptibility of P. aeruginosa to imipenem improved after ertapenem introduction, both according to the proportion of susceptible isolates (P = 0.002) and to the incidence density of resistance (P ≤ 0.001). No significant change was seen in A. baumannii susceptibility to imipenem (P = 0.772). By multiple linear regression analysis, the incidence density of imipenem-resistant P. aeruginosa increased with the use of imipenem (P = 0.003) and ciprofloxacin (P = 0.008). Occurrence of outbreaks (P ≤ 0.001) and use of gentamicin (P = 0.007) were associated with A. baumannii resistance to imipenem. CONCLUSIONS: Use of ertapenem was directly associated with a downward trend in the use of imipenem and ciprofloxacin, which may have contributed to improve the susceptibility of P. aeruginosa to imipenem. Ertapenem use had no impact on the susceptibility of A. baumannii to imipenem.


Assuntos
Acinetobacter baumannii/efeitos dos fármacos , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Imipenem/farmacologia , Pseudomonas aeruginosa/efeitos dos fármacos , Resistência beta-Lactâmica , beta-Lactamas/uso terapêutico , Acinetobacter baumannii/isolamento & purificação , Ciprofloxacino/uso terapêutico , Infecção Hospitalar/tratamento farmacológico , Infecção Hospitalar/microbiologia , Uso de Medicamentos/estatística & dados numéricos , Ecossistema , Ertapenem , Humanos , Testes de Sensibilidade Microbiana , Pseudomonas aeruginosa/isolamento & purificação , Estudos Retrospectivos , Seleção Genética , Centros de Atenção Terciária
6.
Rev. esp. quimioter ; 24(1): 42-47, mar. 2011. tab
Artigo em Inglês | IBECS | ID: ibc-86171

RESUMO

Introducción: Evaluar el uso clínico de linezolid en el tratamiento de las infecciones neuroquirúrgicas. Métodos: Estudio retrospectivo observacional de una cohorte de pacientes hospitalizados que recibieron linezolid para tratamiento de infecciones neuroquirúrgicas con cultivo positivo, desde Julio de 2004 a febrero de 2009 en un hospital terciario español. Resultados: En el estudio se incluyeron 17 pacientes. Las principales comorbilidades fueron una o más de las siguientes: hemorragia subaracnoidea o intraventricular (n= 8), tumor sólido neurológico (n= 7), corticoides (n= 9) e hidrocefalia ( n= 6). Ocho pacientes fueron sometidos a craneotomía y 14 tenían un drenaje ventricular externo (EVD) como factor predisponente de infección. La meningitis fue la infección más común (11; 64,7%), seguida de ventriculitis (4; 23,5%) y absceso cerebral (2; 11,8%). El principal agente causal fue Staphylococcus spp coagulasa negativa (13; 76,5%). Linezolid fue usado como tratamiento incicial en 8 episodios, tras fracaso en 6 y por otras razones en 3. La vía oral fue usada en 9 (52,9%) episodios, de forma inicial en 2 casos. La duración media del tratamiento fue de 26,5 días (rango 15-58). No se observaron efectos adversos. Dieciseís pacientes (94,1%) fueron considerados curados. Hubo una recurrencia. La estancia media en el hospital fue de 45,6 (rango 15-112) días y la duración media del seguimiento fue de 7,2 (rango 0,4-32) meses. No hubo muertes relacionadas con los episodios activos. Coclusiones: Linezolid fue principalmente indicado en las infecciones postquirúrgicas asociadas a EVD por Staphylococcus spp coagulasa negativa. Fue inicialmente usado en la mayoría de los casos. Una alta tasa de curación clínica fue observada y no se detectaron efectos adversos. Más de la mitad de los pacientes se beneficiaron de las ventajas de la vía oral(AU)


Objectives: We sought to evaluate the clinical use of linezolid for the treatment of neurosurgical infections. Methods: Retrospective observational study of a cohort of hospitalized patients who received linezolid for a culture-positive neurosurgical infection from July 2004 to February 2009 in a tertiary hospital in Spain. Results: Seventeen patients were included in the study. Main comorbidities among these patients included one or more of the following: subarachnoidal or intraventricular hemorrhage (n=8), solid neurological cancer (n=7), corticosteroids (n=9) and hydrocephalus (n=6). Eight patients underwent a craniotomy and fourteen patients had an external ventricular drainage (EVD) as predisposing factors for infection. Meningitis was the most common infection (11; 64.7%), followed by ventriculitis (4; 23.5%) and brain abscesses (2; 11.8%). The main causative organisms were coagulase-negative Staphylococcus spp. (13; 76.5%). Linezolid was used as the initial therapy in 8 episodes, after therapy failure in 6 and for other reasons in 3. The oral route was used in 9 (52.9%) episodes; linezolid was initiated orally in 2 cases. The mean duration of treatment was 26.5 days (range 15-58). No adverse events were reported. Sixteen (94.1%) patients were considered cured. There was one recurrence. The mean length of hospital stay was 45.6 (range 15-112) days and the mean duration of follow- up was 7.2 (range 0.4-32) months. No related deaths occurred during active episodes. Conclusions: Linezolid was mainly indicated in post-neurosurgical EVD-associated infections due to coagulase-negative Staphylococcus spp. It was used as initial therapy in most cases. A high rate of clinical cure was observed and no related adverse events were reported. More than half of the patients were benefited by the advantages of the oral route of administration(AU)


Assuntos
Humanos , Masculino , Feminino , Infecção/tratamento farmacológico , Infecção/cirurgia , Procedimentos Neurocirúrgicos/efeitos adversos , Procedimentos Neurocirúrgicos/tendências , Comorbidade , Corticosteroides/uso terapêutico , Hidrocefalia/complicações , Hidrocefalia/tratamento farmacológico , Hidrocefalia/cirurgia , Hemorragia Subaracnóidea/microbiologia , Neurocirurgia/métodos , Estudos Retrospectivos , Craniotomia , Staphylococcus , Staphylococcus/isolamento & purificação , Staphylococcus/patogenicidade , Análise Estatística , Neoplasias do Sistema Nervoso Central/tratamento farmacológico , Neoplasias do Sistema Nervoso Central/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA